Angela Minnella
Company: PTC Therapeutics
Job title: Director, Neuroscience
Seminars:
Panel Discussion: Identifying Targets to Simultaneously Tackle Neuroinflammation & Neurodegeneration 11:15 am
• Debating targets impacting both neuroinflammation and neurodegeneration: RIPKI, ferroptosis, TDP43 • Discussing strategy for targeting two pathological processes simultaneously • Outlining opportunities to de-risk future clinical trials • Debating the future of neuroinflammation modulators as combination therapies in light of recent Alzheimer’s Disease therapeutic approvalsRead more
day: Day Two
Characterizing & Targeting Ferroptosis in Neurodegenerative Disease 11:45 am
• Robust preclinical and clinical evidence suggests that ferroptotic-mediated cell death contributes to neurodegenerative disease • Inhibition of 15-lipoxygenase to prevent ferroptosis addresses primary drivers of disease progression including, accumulation of lipid peroxides, redox imbalance, neuroinflammation, and neuronal loss • Mitigation of lipid peroxidation also serves to address alpha-Synuclein pathology in vitro and in vivoRead more
day: Day Two